標(biāo)題: Titlebook: Cancer Immunotherapy; Methods and Protocol Velia Siciliano,Francesca Ceroni Book 2024 The Editor(s) (if applicable) and The Author(s), unde [打印本頁(yè)] 作者: 使醉 時(shí)間: 2025-3-21 17:30
書目名稱Cancer Immunotherapy影響因子(影響力)
作者: 卡死偷電 時(shí)間: 2025-3-21 23:45
https://doi.org/10.1007/1-4020-4812-2demonstrated during the last 20?years and also recently harnessed for therapy. However, emerging evidence indicates that even neoplasms showing striking initial responses to conventional and targeted (immuno)therapies often acquire resistance, resulting in tumor relapse, increased aggressiveness, an作者: gene-therapy 時(shí)間: 2025-3-22 02:55
Conference proceedings 20061st editionand lymphomas. The synthetic CAR molecule redirects T?cell function toward tumor surface-expressed antigens through a single-chain variable fragment (scFv) fused to CD3z and intracellular costimulatory domains. Here, we describe a protocol for the generation of CAR T cells using primary mouse T cell作者: Observe 時(shí)間: 2025-3-22 08:12 作者: correspondent 時(shí)間: 2025-3-22 12:15
https://doi.org/10.1007/978-981-10-3193-9tive medicine, cancer therapy, and immunoregulation. For example, piezoelectric stimulation has been shown to modulate cytoskeleton variations: the implications of this effect range from the regulation of migration and invasion of cancer cells to the activation of pro- or anti-inflammatory phenotype作者: 拘留 時(shí)間: 2025-3-22 14:06
https://doi.org/10.1007/978-981-10-3193-9niquely suited to improve the development and the broad implementation of cancer immunotherapies by overcoming several challenges. In fact, NMs can be rationally designed to navigate complex physical barriers, respond to tumor microenvironments, and enhance/modulate immune system activation. Here, w作者: 拘留 時(shí)間: 2025-3-22 18:10
https://doi.org/10.1007/978-981-10-3193-9itations such as the number of cells and trained personnel required. To overcome these impediments, here we describe a novel microfluidic platform that can be used to perform FPM assays, optimizing the use of primary cancer cells and simplifying the process by using microfluidics to automatize the p作者: 分解 時(shí)間: 2025-3-23 00:20 作者: 字形刻痕 時(shí)間: 2025-3-23 03:59 作者: Binge-Drinking 時(shí)間: 2025-3-23 08:32 作者: 不透明 時(shí)間: 2025-3-23 10:59 作者: 抗生素 時(shí)間: 2025-3-23 14:58 作者: 北極熊 時(shí)間: 2025-3-23 19:08
https://doi.org/10.1007/978-981-10-3193-9related to basic functional and phenotypic analysis are described. This methodology can be applied to manufacture and assess chimeric antigen receptors for preclinical applications targeting a variety of molecules.作者: BROOK 時(shí)間: 2025-3-24 01:06
https://doi.org/10.1007/978-981-10-3193-9e immune cells, in particular T cells, to desired targets has the potential to lead to the creation of powerful cell-based therapies for a wide range of maladies. While conventional effector T cells (Teff) would be targeted towards cells to be eliminated, such as cancer cells, immunosuppressive regu作者: obstinate 時(shí)間: 2025-3-24 05:47 作者: 游行 時(shí)間: 2025-3-24 09:58 作者: 貴族 時(shí)間: 2025-3-24 12:09
https://doi.org/10.1007/978-981-10-3193-9n receptors (CARs) bear great promise for the treatment of multiple hematological malignancies and solid tumors. Current methods of producing large-scale CAR-NK cells mainly rely on mRNA transfection and viral vector transduction. However, mRNA CAR-NK cells were not stable in CAR expression while vi作者: NOCT 時(shí)間: 2025-3-24 18:02
https://doi.org/10.1007/978-3-031-37387-9cribe the development of a probiotic . Nissle 1917 platform encoding a synchronized lysis mechanism for the localized and sustained release of blocking nanobodies against immune checkpoint molecules like programmed cell death protein-ligand 1 and cytotoxic T lymphocyte–associated protein-4. Specific作者: Ascribe 時(shí)間: 2025-3-24 22:50
https://doi.org/10.1007/978-1-0716-3593-3CAR-T cells; NK-resistant lymphomas; cancer cells phagocytosis; lymphoblastic leukemia; SUPRA-CARs作者: Mnemonics 時(shí)間: 2025-3-25 01:05 作者: 痛打 時(shí)間: 2025-3-25 04:23
https://doi.org/10.1007/1-4020-4812-2Retroviral transduction is a highly useful tool to genetically engineer hard-to-transfect human primary cells. Here, we transduce human primary T cells with a tumor-specific T cell receptor. This creates a useful tool to analyze T cell–cancer cell interactions, such as cytolysis analysis using xCELLigence technology.作者: 增長(zhǎng) 時(shí)間: 2025-3-25 07:54 作者: FEMUR 時(shí)間: 2025-3-25 14:06 作者: endoscopy 時(shí)間: 2025-3-25 17:27 作者: Pandemic 時(shí)間: 2025-3-25 21:38
https://doi.org/10.1007/978-981-10-3193-9related to basic functional and phenotypic analysis are described. This methodology can be applied to manufacture and assess chimeric antigen receptors for preclinical applications targeting a variety of molecules.作者: 動(dòng)脈 時(shí)間: 2025-3-26 02:35 作者: aviator 時(shí)間: 2025-3-26 05:55
Methods in Molecular Biologyhttp://image.papertrans.cn/c/image/221137.jpg作者: otic-capsule 時(shí)間: 2025-3-26 08:59
A New Microfluidic Device to Facilitate Functional Precision Medicine Assays,itations such as the number of cells and trained personnel required. To overcome these impediments, here we describe a novel microfluidic platform that can be used to perform FPM assays, optimizing the use of primary cancer cells and simplifying the process by using microfluidics to automatize the process.作者: 串通 時(shí)間: 2025-3-26 15:18 作者: Uncultured 時(shí)間: 2025-3-26 20:50
1064-3745 ng-edge,?.Cancer Immunotherapy: Methods and Protocols .aims to ensure successful results in the further study of this vital field..978-1-0716-3595-7978-1-0716-3593-3Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: beta-carotene 時(shí)間: 2025-3-26 23:56
In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow ots of therapy failure. Flow cytometry is a powerful technology that finds extensive applications in cancer biology. It offers several unique advantages as it allows the rapid, quantitative, and multiparametric analysis of cell populations or functions at the single-cell level. In this chapter, we d作者: 古董 時(shí)間: 2025-3-27 03:01
https://doi.org/10.1007/1-4020-4812-2ots of therapy failure. Flow cytometry is a powerful technology that finds extensive applications in cancer biology. It offers several unique advantages as it allows the rapid, quantitative, and multiparametric analysis of cell populations or functions at the single-cell level. In this chapter, we d作者: 貴族 時(shí)間: 2025-3-27 07:09 作者: bifurcate 時(shí)間: 2025-3-27 10:59
1064-3745 ation advice from the experts.This volume details multiple areas of new and emerging methods to develop the next generation of immunotherapy treatments. Chapters guide readers through analysis and characterisation of the interactions between tumour and immune cells, and cell engineering tools for ca作者: 鬧劇 時(shí)間: 2025-3-27 14:32
https://doi.org/10.1007/978-981-10-3193-9ess this issue, a nano-optogenetic approach has been developed to enable spatiotemporal control of CAR-T cell activity. This system is comprised of synthetic light-sensitive CAR-T cells and upconversion nanoparticles acting as an in situ nanotransducer, allowing near-infrared light to wirelessly control CAR-T cell immunotherapy.作者: DNR215 時(shí)間: 2025-3-27 18:02 作者: isotope 時(shí)間: 2025-3-28 01:21 作者: 可忽略 時(shí)間: 2025-3-28 06:02 作者: Countermand 時(shí)間: 2025-3-28 07:29
Monitoring Cell Cytoskeleton Variations upon Piezoelectric Stimulation: Implications for the Immunes in immune cells. In this chapter, we will present different methodologies to evaluate cytoskeleton variations, focusing on modifications on ./.actin ratio and on the migration and invasion ability of tumor cells.作者: BADGE 時(shí)間: 2025-3-28 11:04 作者: 大氣層 時(shí)間: 2025-3-28 17:43
Genetic Modification of Tumor-Infiltrating Lymphocytes, Peripheral T Cells, and T-Cell Model Cell Lenetically modified TILs. The protocol includes instructions for retroviral transduction and mRNA transfection of circulating T cells or T-cell lines. The GOIs most commonly introduced into the target cells are chimeric antigen receptors (CARs); genetic adjuvants, such as membrane-bound interleukins; and antitumor T-cell receptors (TCRs).作者: Sarcoma 時(shí)間: 2025-3-28 21:43 作者: 拔出 時(shí)間: 2025-3-29 00:32 作者: 包租車船 時(shí)間: 2025-3-29 05:13
https://doi.org/10.1007/978-981-10-3193-9resent chapter, we provide a protocol to identify and characterize the time evolution of apoptosis by time-lapse fluorescence and confocal imaging in a 3D microfluidic coculture murine model including cancer and spleen cells.作者: lactic 時(shí)間: 2025-3-29 10:39 作者: 鞏固 時(shí)間: 2025-3-29 12:39 作者: 符合國(guó)情 時(shí)間: 2025-3-29 17:19
https://doi.org/10.1007/978-981-10-3193-9argets for their capacity to infiltrate and eliminate human solid tumors in vivo. Here, we provide a detailed protocol to evaluate human CAR CD4. helper T cells and CD8. cytotoxic T cells in immunodeficient (NSG) mice bearing antigen-expressing human solid tumors.作者: 策略 時(shí)間: 2025-3-29 19:56
https://doi.org/10.1007/978-981-10-3193-9 . transposon system via electroporation and to further expand these engineered CAR-NK cells in a large scale together with artificial antigen-presenting feeder cells. This method can stably engineer human primary NK cells with high efficiency and supply sufficient scale of engineered CAR-NK cells for the future possible clinical applications.作者: 極少 時(shí)間: 2025-3-30 00:51 作者: 出價(jià) 時(shí)間: 2025-3-30 05:26 作者: 親密 時(shí)間: 2025-3-30 11:41 作者: Guileless 時(shí)間: 2025-3-30 14:45
Redirecting Human Conventional and Regulatory T Cells Using Chimeric Antigen Receptors,olecules comprising an extracellular recognition domain and an intracellular signaling domain that drives full T cell activation directly downstream of target binding. Here, we describe procedures to generate and evaluate human CAR CD4. helper T cells, CD8. cytotoxic T cells, and CD4.FOXP3. regulatory T cells.作者: 蓋他為秘密 時(shí)間: 2025-3-30 17:22
How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy,argets for their capacity to infiltrate and eliminate human solid tumors in vivo. Here, we provide a detailed protocol to evaluate human CAR CD4. helper T cells and CD8. cytotoxic T cells in immunodeficient (NSG) mice bearing antigen-expressing human solid tumors.作者: AVOW 時(shí)間: 2025-3-31 00:21
A Nonviral , Transposon-Mediated Method to Generate Large-Scale CAR-NK Cells from Human Peripheral . transposon system via electroporation and to further expand these engineered CAR-NK cells in a large scale together with artificial antigen-presenting feeder cells. This method can stably engineer human primary NK cells with high efficiency and supply sufficient scale of engineered CAR-NK cells for the future possible clinical applications.作者: 萬(wàn)靈丹 時(shí)間: 2025-3-31 01:25
Conference proceedings 20061st editions and a gammaretroviral vector encoding a CAR transgene. This protocol outlines several transduction and expansion methods based on the use of two transduction enhancers, RetroNectin. and Vectofusin.-1, and cell culture systems such as conventional plates or G-Rex. devices.作者: 遷移 時(shí)間: 2025-3-31 08:17 作者: defenses 時(shí)間: 2025-3-31 11:38 作者: 填滿 時(shí)間: 2025-3-31 14:52 作者: 值得贊賞 時(shí)間: 2025-3-31 19:14 作者: Ejaculate 時(shí)間: 2025-3-31 22:38
https://doi.org/10.1007/978-3-031-37387-9ally, we will detail the experimental protocols needed to (1) encode and validate binding of recombinantly produced checkpoint blockade nanobodies, (2) evaluate the therapeutic efficacy and safety of the probiotic platform in syngeneic tumor-bearing mice, and (3) analyze the immunophenotype of the tumor microenvironment.作者: BADGE 時(shí)間: 2025-4-1 03:18 作者: MOAN 時(shí)間: 2025-4-1 08:48 作者: 文藝 時(shí)間: 2025-4-1 13:04
